| Institution: | 1. Helmholtz Institute for Pharmaceutical Research Saarland, Department Microbial Natural Products, Helmholtz Centre for Infection Research and Pharmaceutical Biotechnology, Saarland University, Saarbrücken, Germany;2. German Center for Infection Research (DZIF), Partner Site Bonn-Cologne (JR) and partner site Hannover-Braunschweig (JH, RM), Germany;3. Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany;4. Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany;1. Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada;2. Department of Biochemistry, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Canada;3. Department of Oncology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Canada;1. DST/NRF Centre of Excellence for Biomedical TB Research, Faculty of Health Sciences, University of the Witwatersrand, National Health Laboratory Service, Johannesburg, South Africa;2. Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA;3. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA;4. TB Discovery Research, Infectious Disease Research Institute, Seattle, WA 98102, USA;5. Department of Microbiology, Yong Loo Lin School of Medicine, National University Health System, National University of Singapore, Republic of Singapore;2. Laboratoire de Dynamique des Interactions Membranaires Normales et Pathologiques, Université de Montpellier, CNRS, UMR 5235, Montpellier, France |
